Wednesday, 5 December 2018

Combioxin Announces an Oral Presentation on CAL02 clinical results


Combioxin SA, a clinical-stage biotechnology company focused on the development of innovative treatments for severe and resistant infections, announced today that first-in-human clinical results with CAL02 in severe pneumonia patients in ICU was presented during the ESICM’s annual congress, LIVES 2018, taking place October 20-24, 2018 in Paris, France. A recording is available:

Presentation details were as follows:

  • Session: Management of patients with sepsis
  • Title: Adjunctive intravenous anti-toxin treatment with CAL02 in severe acute communityacquired pneumonia due to Streptococcus pneumoniae.  A first-in-man, multicentre, double-blind, placebo-controlled study
  • Presenter: Pierre-François Laterre, Cliniques universitaires Saint-Luc, Université catholique de Louvain (UCL), Brussels, Belgium Date: Wednesday, October 24, 2018 Time: 10:10 AM Location: Barcelona Hall, Palais des Congrès, Paris, France  Presentation number: 0995
CAL02 is a novel liposomal agent that acts as a toxin-trap by mimicking microdomains used as cellular docking stations by various bacterial toxins which prompt inflammatory bursts, cause organ damages, favor invasiveness, impede immune defenses, and are also involved in mechanisms of resistance. CAL02 is designed to protect against these deleterious reactions, allowing a faster resolution of organ dysfunction and protecting immune responses. CAL02 is active against toxins produced by major pathogens responsible for common and severe infections including those caused by drug-resistant pathogens.

Posted by Dr. Tim Sandle, Pharmaceutical Microbiology

Special offers